- Indication: Psoriatic Arthritis
- Enrollment Status: Enrollment Open
- Protocol: TAK279PsA3001
- Drug: Bimekizumab
- Sponsor: UCB Pharma
- Description: PA0016- A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis
